View Valuation3SBio 향후 성장Future 기준 점검 0/63SBio 의 수익과 수익은 각각 연간 14.5% 및 40.1% 감소할 것으로 예상됩니다. EPS는 연간 41.6% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 8.7% 로 예상됩니다.핵심 정보-40.1%이익 성장률-41.60%EPS 성장률Biotechs 이익 성장25.2%매출 성장률-14.5%향후 자기자본이익률8.69%애널리스트 커버리지Good마지막 업데이트16 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 023SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026.공시 • Mar 313SBio Inc., Annual General Meeting, Jun 25, 20263SBio Inc., Annual General Meeting, Jun 25, 2026.공시 • Mar 173SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 20263SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026공시 • Dec 103SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listing공시 • Dec 033SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listing공시 • Aug 193SBio Inc. to Report First Half, 2025 Results on Aug 29, 20253SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025공시 • Aug 013SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,142,500 Price\Range: HKD 25.2055공시 • Jun 25+ 1 more update3SBio Inc. Declares Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 20253SBio Inc. announced that At the AGM held on 25 June 2025, declared a final dividend of 25 HK cents per ordinary share for the year ended 31 December 2024. As the resolution numbered 3 for the payment of the Final Dividend was duly passed at the AGM, subject to the fulfilment of the other condition as stated in the Circular, the Company will pay the Final Dividend for the year ended 31 December 2024 to the Shareholders whose names appear on the register of members of the Company as at the close of business on 25 July 2025 (the "Record Date"), and the payment date is expected to be 15 August 2025.공시 • Apr 173SBio Inc. Receives Breakthrough Therapy Designation by China's National Medical Products Administration3SBio Inc. on a voluntary basis. On 17 April, 2025, the anti-VEGF/PD-1 bispecific antibody (R&D code: 707 Injection), independently developed by 3SBio, was granted a Breakthrough Therapy Designation ("BTD") by China's National Medical Products Administration (" NMPA"). The designated indication is the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer ("NSCLC"). 707 Injection is a bispecific antibody targeting VEGF/PD-1, independently developed by 3SBio based on its proprietary CLF2 platform. It is currently undergoing multiple clinical studies in China, including a phase III clinical study for the first-line treatment ofPD-1 positive locally advanced and metastatic NSCLC already approved by the Center for Drug Evaluation ("CDE") of the NMPA. Additionally, 707 Injection is undergoing several phase II studies in China, including combination therapy with chemotherapy for the first-line treatment of advanced NSCLC, metastatic colorectal cancer, and advanced gynecological tumours. It has also received approval from the U.S. Food and Drug Administration in relation to its Investigational New Drug application. The CDE will provide policy support for drugs that have been granted BTDs, prioritize resource allocation for communication, enhance guidance, and accelerate drug development. When submitting a New Drug Application, if it is evaluated to meet the relevant conditions, the qualification for priority review and approval may be granted, expediting the market launch process. There is no assurance that the product will eventually be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.공시 • Mar 253SBio Inc., Annual General Meeting, Jun 25, 20253SBio Inc., Annual General Meeting, Jun 25, 2025.공시 • Mar 073SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 20253SBio Inc. announced that they will report fiscal year 2024 results on Mar 25, 2025공시 • Aug 123SBio Inc. to Report First Half, 2024 Results on Aug 22, 20243SBio Inc. announced that they will report first half, 2024 results on Aug 22, 2024공시 • Apr 233Sbio Inc. Announces Management Changes3SBio Inc. announced that in accordance with the articles of association of the Company, Dr. ZHANG Dan ("Dr. Zhang"), an independent non-executive Director, will retire by rotation at the forthcoming annual general meeting (the "AGM") of the Company which is to be held on 25 June 2024. He will not seek for re-election due to his other business commitments. His retirement will take effect upon the conclusion of the AGM and, accordingly, he will cease to be a member of the remuneration committee of the Board ("Remuneration Committee") at the conclusion of the AGM. The Board further announces that Mr. NG, Joo Yeow Gerry, an independent non-executive Director, has been appointed by the Board as a member of the Remuneration Committee with effect immediately after the conclusion of the 2023 AGM to be held on 25 June 2024.공시 • Mar 21+ 1 more update3SBio Inc., Annual General Meeting, Jun 25, 20243SBio Inc., Annual General Meeting, Jun 25, 2024.공시 • Mar 063SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 20243SBio Inc. announced that they will report fiscal year 2023 results on Mar 20, 2024공시 • Jan 09Mandi Foam of 3SBio Inc. Approves for Market Launch3SBio Inc. announced that the application for market launch of Mandi (5% minoxidil) Foam as an over-the-counter drug for the treatment of androgenetic alopecia and alopecia areata by its subsidiary, Zhejiang Wansheng Pharmaceutical Co. Ltd., to the National Medical Products Administration (NMPA) of the PRC has been approved. Mandi Foam is the new-generation anti-hair loss and hair growth product of 3SBio group based on Minoxidil Tincture (trade name: Mandi), which is also the first domestic minoxidil foam approved for market launch. Previously, the result of such product in "a multi-centered, double-blind, randomized controlled clinical trial to assess the efficacy of Mandi Foam and ROGAINE® (5% Minoxidil Foam) on patients with androgenetic alopecia in terms of their equivalence, safety and tolerability" reached the preset statistical end point, indicating that the efficacy of Mandi Foam is equivalent to that of the controlled medicine, ROGAINE®. Minoxidil is currently a first-line topical drug for the clinical treatment of androgenetic alopecia. Mandi Foam has better transdermal speed and scalp accumulation rate, with milder scalp tolerance, rendering it a better choice for alopecia users.공시 • Aug 123SBio Inc. to Report First Half, 2023 Results on Aug 24, 20233SBio Inc. announced that they will report first half, 2023 results on Aug 24, 2023공시 • Jul 293Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer3SBio Inc. announced that with effect from 3 July 2023, Mr. HE Xiang ("Mr. He") has been appointed as the new chief financial officer of the Company. Mr. He will be responsible for investment and finance activities, as well as investor relations management of the Group. The biographical details of Mr. He are as follows: Mr. He graduated from the Guanghua School of Management of Peking University with a master degree in Finance. He has served Citigroup and J.P. Morgan investment banking in Beijing, Shanghai, New York and Hong Kong, and has 15 years of experience in investments, financings, and capital markets. He is a registered sponsor principal with the Securities and Futures Commission of Hong Kong. During his tenure in J.P. Morgan, he held different roles including Head of Corporated Finance and Head of Financial Institutions for China, and gained extensive experiences in equity private placements, initial public offerings, follow-on offerings and mergers and acquisitions for various corporates across pharmaceutical, healthcare as well as other sectors.공시 • Jul 063SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market3SBio Inc. announced that the new drug application of narfuraphine hydrochloride orally disintegrating tablets submitted to the National Medical Products Administration of China (NMPA) being approved for launch in the market. This is a voluntary announcement made by the Company. There is no assurance that the Company will eventually successfully launch and/or commercialize the product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. 3SBio Inc. announced that The new drug application of narfurphine hydrochloride orally disintegrated tablets (Li Mei Zhi®?, trade name in Japan; " remitsuchiODDING 2.5ug") submitted To the National Medical Products Administration ofChina (NMPA) has been approved (Guoyaozhunzi No. HJ20230091) for the improvement of pruritus in hemodialysis patients (only in cases where the efficacy of existing treatments is not satisfactory). This is the first and only selective k (kappa)-opioid receptor agonist approved by the NMPA to treat hemodialysis patients with refractory pruritus. In addition, the clinical trial application for this product to improve pruritus in patients with chronic liver disease (only in cases where the effectiveness of existing treatments is not satisfactory) was approved in May this year (Notice No.: 2023LP00912). Hemodialysis patients are often accompanied by various complications such as anemia, hypertension, abnormal calcium and phosphorus metabolism, hyperthyroidism, and pruritus. Currently, there is still no recognized effective treatment for pruritus in most of the patients, which causes great mental and physical pain to the patients and significantly reduces their quality of life.공시 • May 23+ 3 more updates3SBio Inc., Annual General Meeting, Jun 20, 20233SBio Inc., Annual General Meeting, Jun 20, 2023, at 10:00 China Standard Time. Location: No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone Shenyang China Agenda: To receive and adopt the audited financial statements of the Company for the year ended 31 December 2022 and the reports of the directors and auditors thereon; to declare and pay a final dividend of HKD 10 cents per ordinary share for the year ended 31 December 2022 out of the Company's share premium account to the shareholders of the Company whose name appear on the register of members of the Company as at the close of business on Monday, 3 July 2023; to re-appoint Ernst & Young as auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration for the year ending 31 December 2023; and to consider other matters.공시 • Jan 043SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director3SBio Inc. provided supplemental information on the resignation of Mr. Tang Ke. Mr. Tang tendered his resignation as a non-executive Director as he needs to devote more time to his personal commitments and there are no other matters in respect of his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange.이익 및 매출 성장 예측OTCPK:TRSB.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202811,9053,1593,8503,728912/31/202711,2892,9523,2423,5771312/31/202610,4712,8232,7153,6291212/31/202517,6968,4829,1289,669N/A9/30/202513,3855,4205,6366,373N/A6/30/20259,0742,3592,1453,078N/A3/31/20259,0912,2242,1923,140N/A12/31/20249,1082,0902,2383,201N/A9/30/20248,7651,8741,7672,596N/A6/30/20248,4221,6591,2971,991N/A3/31/20248,1191,6041,3382,037N/A12/31/20237,8161,5491,3792,083N/A9/30/20237,6861,7391,3212,187N/A6/30/20237,5551,9291,2642,291N/A3/31/20237,2101,9231,2122,213N/A12/31/20226,8661,9161,1592,134N/A9/30/20226,6181,8171,0081,964N/A6/30/20226,3691,7198561,794N/A3/31/20226,3761,6856631,686N/A12/31/20216,3821,6514691,578N/A9/30/20216,1911,3423941,513N/A6/30/20216,0001,0323181,448N/A3/31/20215,7949343401,396N/A12/31/20205,5888363631,345N/A9/30/20205,4791,0958131,620N/A6/30/20205,3701,3551,2631,896N/A3/31/20205,3441,1641,3321,892N/A12/31/20195,3189741,4011,887N/A9/30/20195,1851,029N/A1,645N/A6/30/20195,0531,084N/A1,403N/A3/31/20194,8181,181N/A1,277N/A12/31/20184,5841,277N/A1,150N/A9/30/20184,3931,167N/A1,160N/A6/30/20184,2021,057N/A1,171N/A3/31/20183,968996N/A1,122N/A12/31/20173,734935N/A1,074N/A9/30/20173,467877N/A1,017N/A6/30/20173,199818N/A960N/A3/31/20172,998766N/A982N/A12/31/20162,797713N/A1,004N/A9/30/20162,492642N/A794N/A6/30/20162,188571N/A583N/A3/31/20161,930548N/A519N/A12/31/20151,673526N/A455N/A9/30/20151,503456N/A521N/A6/30/20151,364341N/A534N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: TRSB.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -40.1%).수익 vs 시장: TRSB.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -40.1%).고성장 수익: TRSB.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다.수익 대 시장: TRSB.F 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -14.5%).고성장 매출: TRSB.F 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -14.5%).주당순이익 성장 예측향후 자기자본이익률미래 ROE: TRSB.F의 자본 수익률은 3년 후 8.7%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/18 14:51종가2026/05/08 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스3SBio Inc.는 35명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bo YuChina International Capital Corporation LimitedZhuhong ChenChina Merchants Securities (HK) Co., LtdShitong HanCitic Securities Co., Ltd.32명의 분석가 더 보기
공시 • Apr 023SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026.
공시 • Mar 313SBio Inc., Annual General Meeting, Jun 25, 20263SBio Inc., Annual General Meeting, Jun 25, 2026.
공시 • Mar 173SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 20263SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026
공시 • Dec 103SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listing
공시 • Dec 033SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 105,169,500 Price\Range: HKD 29.62 Transaction Features: Subsequent Direct Listing
공시 • Aug 193SBio Inc. to Report First Half, 2025 Results on Aug 29, 20253SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025
공시 • Aug 013SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million.3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,142,500 Price\Range: HKD 25.2055
공시 • Jun 25+ 1 more update3SBio Inc. Declares Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 20253SBio Inc. announced that At the AGM held on 25 June 2025, declared a final dividend of 25 HK cents per ordinary share for the year ended 31 December 2024. As the resolution numbered 3 for the payment of the Final Dividend was duly passed at the AGM, subject to the fulfilment of the other condition as stated in the Circular, the Company will pay the Final Dividend for the year ended 31 December 2024 to the Shareholders whose names appear on the register of members of the Company as at the close of business on 25 July 2025 (the "Record Date"), and the payment date is expected to be 15 August 2025.
공시 • Apr 173SBio Inc. Receives Breakthrough Therapy Designation by China's National Medical Products Administration3SBio Inc. on a voluntary basis. On 17 April, 2025, the anti-VEGF/PD-1 bispecific antibody (R&D code: 707 Injection), independently developed by 3SBio, was granted a Breakthrough Therapy Designation ("BTD") by China's National Medical Products Administration (" NMPA"). The designated indication is the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer ("NSCLC"). 707 Injection is a bispecific antibody targeting VEGF/PD-1, independently developed by 3SBio based on its proprietary CLF2 platform. It is currently undergoing multiple clinical studies in China, including a phase III clinical study for the first-line treatment ofPD-1 positive locally advanced and metastatic NSCLC already approved by the Center for Drug Evaluation ("CDE") of the NMPA. Additionally, 707 Injection is undergoing several phase II studies in China, including combination therapy with chemotherapy for the first-line treatment of advanced NSCLC, metastatic colorectal cancer, and advanced gynecological tumours. It has also received approval from the U.S. Food and Drug Administration in relation to its Investigational New Drug application. The CDE will provide policy support for drugs that have been granted BTDs, prioritize resource allocation for communication, enhance guidance, and accelerate drug development. When submitting a New Drug Application, if it is evaluated to meet the relevant conditions, the qualification for priority review and approval may be granted, expediting the market launch process. There is no assurance that the product will eventually be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.
공시 • Mar 253SBio Inc., Annual General Meeting, Jun 25, 20253SBio Inc., Annual General Meeting, Jun 25, 2025.
공시 • Mar 073SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 20253SBio Inc. announced that they will report fiscal year 2024 results on Mar 25, 2025
공시 • Aug 123SBio Inc. to Report First Half, 2024 Results on Aug 22, 20243SBio Inc. announced that they will report first half, 2024 results on Aug 22, 2024
공시 • Apr 233Sbio Inc. Announces Management Changes3SBio Inc. announced that in accordance with the articles of association of the Company, Dr. ZHANG Dan ("Dr. Zhang"), an independent non-executive Director, will retire by rotation at the forthcoming annual general meeting (the "AGM") of the Company which is to be held on 25 June 2024. He will not seek for re-election due to his other business commitments. His retirement will take effect upon the conclusion of the AGM and, accordingly, he will cease to be a member of the remuneration committee of the Board ("Remuneration Committee") at the conclusion of the AGM. The Board further announces that Mr. NG, Joo Yeow Gerry, an independent non-executive Director, has been appointed by the Board as a member of the Remuneration Committee with effect immediately after the conclusion of the 2023 AGM to be held on 25 June 2024.
공시 • Mar 21+ 1 more update3SBio Inc., Annual General Meeting, Jun 25, 20243SBio Inc., Annual General Meeting, Jun 25, 2024.
공시 • Mar 063SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 20243SBio Inc. announced that they will report fiscal year 2023 results on Mar 20, 2024
공시 • Jan 09Mandi Foam of 3SBio Inc. Approves for Market Launch3SBio Inc. announced that the application for market launch of Mandi (5% minoxidil) Foam as an over-the-counter drug for the treatment of androgenetic alopecia and alopecia areata by its subsidiary, Zhejiang Wansheng Pharmaceutical Co. Ltd., to the National Medical Products Administration (NMPA) of the PRC has been approved. Mandi Foam is the new-generation anti-hair loss and hair growth product of 3SBio group based on Minoxidil Tincture (trade name: Mandi), which is also the first domestic minoxidil foam approved for market launch. Previously, the result of such product in "a multi-centered, double-blind, randomized controlled clinical trial to assess the efficacy of Mandi Foam and ROGAINE® (5% Minoxidil Foam) on patients with androgenetic alopecia in terms of their equivalence, safety and tolerability" reached the preset statistical end point, indicating that the efficacy of Mandi Foam is equivalent to that of the controlled medicine, ROGAINE®. Minoxidil is currently a first-line topical drug for the clinical treatment of androgenetic alopecia. Mandi Foam has better transdermal speed and scalp accumulation rate, with milder scalp tolerance, rendering it a better choice for alopecia users.
공시 • Aug 123SBio Inc. to Report First Half, 2023 Results on Aug 24, 20233SBio Inc. announced that they will report first half, 2023 results on Aug 24, 2023
공시 • Jul 293Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer3SBio Inc. announced that with effect from 3 July 2023, Mr. HE Xiang ("Mr. He") has been appointed as the new chief financial officer of the Company. Mr. He will be responsible for investment and finance activities, as well as investor relations management of the Group. The biographical details of Mr. He are as follows: Mr. He graduated from the Guanghua School of Management of Peking University with a master degree in Finance. He has served Citigroup and J.P. Morgan investment banking in Beijing, Shanghai, New York and Hong Kong, and has 15 years of experience in investments, financings, and capital markets. He is a registered sponsor principal with the Securities and Futures Commission of Hong Kong. During his tenure in J.P. Morgan, he held different roles including Head of Corporated Finance and Head of Financial Institutions for China, and gained extensive experiences in equity private placements, initial public offerings, follow-on offerings and mergers and acquisitions for various corporates across pharmaceutical, healthcare as well as other sectors.
공시 • Jul 063SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market3SBio Inc. announced that the new drug application of narfuraphine hydrochloride orally disintegrating tablets submitted to the National Medical Products Administration of China (NMPA) being approved for launch in the market. This is a voluntary announcement made by the Company. There is no assurance that the Company will eventually successfully launch and/or commercialize the product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. 3SBio Inc. announced that The new drug application of narfurphine hydrochloride orally disintegrated tablets (Li Mei Zhi®?, trade name in Japan; " remitsuchiODDING 2.5ug") submitted To the National Medical Products Administration ofChina (NMPA) has been approved (Guoyaozhunzi No. HJ20230091) for the improvement of pruritus in hemodialysis patients (only in cases where the efficacy of existing treatments is not satisfactory). This is the first and only selective k (kappa)-opioid receptor agonist approved by the NMPA to treat hemodialysis patients with refractory pruritus. In addition, the clinical trial application for this product to improve pruritus in patients with chronic liver disease (only in cases where the effectiveness of existing treatments is not satisfactory) was approved in May this year (Notice No.: 2023LP00912). Hemodialysis patients are often accompanied by various complications such as anemia, hypertension, abnormal calcium and phosphorus metabolism, hyperthyroidism, and pruritus. Currently, there is still no recognized effective treatment for pruritus in most of the patients, which causes great mental and physical pain to the patients and significantly reduces their quality of life.
공시 • May 23+ 3 more updates3SBio Inc., Annual General Meeting, Jun 20, 20233SBio Inc., Annual General Meeting, Jun 20, 2023, at 10:00 China Standard Time. Location: No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone Shenyang China Agenda: To receive and adopt the audited financial statements of the Company for the year ended 31 December 2022 and the reports of the directors and auditors thereon; to declare and pay a final dividend of HKD 10 cents per ordinary share for the year ended 31 December 2022 out of the Company's share premium account to the shareholders of the Company whose name appear on the register of members of the Company as at the close of business on Monday, 3 July 2023; to re-appoint Ernst & Young as auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration for the year ending 31 December 2023; and to consider other matters.
공시 • Jan 043SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director3SBio Inc. provided supplemental information on the resignation of Mr. Tang Ke. Mr. Tang tendered his resignation as a non-executive Director as he needs to devote more time to his personal commitments and there are no other matters in respect of his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange.